Eltrombopag to raise low platelets after chemotherapy
Treatments studied
Part of Blood & lymphatic clinical trials.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can participate in the study consent and follow-up.
- You have chemotherapy-related thrombocytopenia (low platelets) that did not improve after repeat treatment with TPO or IL-11 medicines.
- You have stopped chemotherapy or radiation for more than 1 month.
- Your platelet count is under 30, and you have a bleeding tendency (bleeding risk).
- Your liver and kidney tests are not too abnormal (less than 1.5× the lab’s normal limit).
- You are able to use effective birth control; if you could become pregnant, your pregnancy test must be negative.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies herombopag to raise very low platelet counts caused by chemotherapy and reduce bleeding risk. It may help people whose platelet levels stay too low even after prior standard attempts like rhTPO or IL-11.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
This study tests a medication called hetrombopag, which helps raise platelet counts. It's for people with acute myeloid leukemia who have low platelets after intensive chemotherapy and are in remission.
This study tests an oral medication, hetrombopag, to see if it can safely raise platelet counts in people with gynecologic cancers whose platelets drop too low from chemotherapy or other cancer treatments. It may help them continue their cancer therapy without delays or bleeding risks.
This study tests whether adding another medicine (telitacicept) to a standard platelet-boosting drug (eltrombopag) works better than eltrombopag alone for adults with ITP that hasn't improved with steroids. The goal is to help raise your platelet counts and reduce bleeding risk.
This trial studies a pill called herombopag to see if it can prevent low blood platelets caused by chemotherapy (and sometimes radiation) in people with cervical cancer. Low platelets increase the risk of bleeding, and this drug may help keep platelet levels safer so you can continue your cancer treatment.
Hear when a new Chemotherapy Induced Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.